Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.24
PTLA's Cash-to-Debt is ranked lower than
60% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PTLA: 3.24 )
Ranked among companies with meaningful Cash-to-Debt only.
PTLA' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.24  Med: No Debt Max: No Debt
Current: 3.24
Equity-to-Asset 0.47
PTLA's Equity-to-Asset is ranked lower than
64% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PTLA: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
PTLA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.31  Med: 0.82 Max: 0.91
Current: 0.47
-1.31
0.91
Piotroski F-Score: 2
Altman Z-Score: 2.12
Beneish M-Score: -4.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -756.21
PTLA's Operating Margin % is ranked lower than
74% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. PTLA: -756.21 )
Ranked among companies with meaningful Operating Margin % only.
PTLA' s Operating Margin % Range Over the Past 10 Years
Min: -1882.15  Med: -759.31 Max: 25.46
Current: -756.21
-1882.15
25.46
Net Margin % -759.21
PTLA's Net Margin % is ranked lower than
75% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. PTLA: -759.21 )
Ranked among companies with meaningful Net Margin % only.
PTLA' s Net Margin % Range Over the Past 10 Years
Min: -1876.59  Med: -757.78 Max: 25.61
Current: -759.21
-1876.59
25.61
ROE % -95.99
PTLA's ROE % is ranked lower than
76% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PTLA: -95.99 )
Ranked among companies with meaningful ROE % only.
PTLA' s ROE % Range Over the Past 10 Years
Min: -159.12  Med: -72.76 Max: -42.58
Current: -95.99
-159.12
-42.58
ROA % -65.61
PTLA's ROA % is ranked lower than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PTLA: -65.61 )
Ranked among companies with meaningful ROA % only.
PTLA' s ROA % Range Over the Past 10 Years
Min: -65.61  Med: -36.15 Max: 20.67
Current: -65.61
-65.61
20.67
ROC (Joel Greenblatt) % -3828.38
PTLA's ROC (Joel Greenblatt) % is ranked lower than
79% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PTLA: -3828.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTLA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5117.78  Med: -3717.97 Max: 1029.06
Current: -3828.38
-5117.78
1029.06
3-Year Revenue Growth Rate 10.90
PTLA's 3-Year Revenue Growth Rate is ranked higher than
60% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. PTLA: 10.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTLA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.6 Max: 10.9
Current: 10.9
0
10.9
3-Year EBITDA Growth Rate 9.30
PTLA's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. PTLA: 9.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PTLA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.3
Current: 9.3
0
9.3
3-Year EPS without NRI Growth Rate 9.30
PTLA's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PTLA: 9.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTLA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.3
Current: 9.3
0
9.3
GuruFocus has detected 3 Warning Signs with Portola Pharmaceuticals Inc $PTLA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTLA's 30-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PTLA Guru Trades in Q2 2016

Ken Fisher 82,737 sh (+3.03%)
Steven Cohen Sold Out
Paul Tudor Jones 24,761 sh (-18.66%)
Jim Simons 349,400 sh (-26.41%)
Eaton Vance Worldwide Health Sciences Fund 467,200 sh (-35.62%)
» More
Q3 2016

PTLA Guru Trades in Q3 2016

Ken Fisher 82,737 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Jim Simons 161,500 sh (-53.78%)
» More
Q4 2016

PTLA Guru Trades in Q4 2016

Jim Simons Sold Out
Ken Fisher 46,637 sh (-43.63%)
» More
Q1 2017

PTLA Guru Trades in Q1 2017

Joel Greenblatt 27,710 sh (New)
Ken Fisher 46,637 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PRTA, NYSE:AXON, NAS:CLVS, NAS:AGIO, NAS:LGND, NAS:RARE, NAS:SAGE, NAS:TBPH, OTCPK:MPSYY, NAS:JUNO, NAS:SRPT, NAS:AVXS, OTCPK:ABCZY, NAS:FGEN, NAS:DBVT, NYSE:CBM, OTCPK:BVNRY, NAS:HALO, NAS:ONCE, NAS:ICPT » details
Traded in other countries:0PP.Germany,
Headquarter Location:USA
Portola Pharmaceuticals Inc is a biopharmaceutical company. It develops & commercializes novel therapeutics in the areas of thrombosis, other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options.

Portola Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.

Top Ranked Articles about Portola Pharmaceuticals Inc

Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17

SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the Company’s investigational drug betrixaban will be presented in a poster session at the upcoming American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo, which is taking place from March 17-19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, clinical data on betrixaban and on the Company’s investigational agent AndexXa™ (andexanet alfa) will be discussed during an oral session titled, “Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention.” Betrixaban, which has Fast Track designation from the U.S. Food and Drug Administration (FDA), is an oral, once-daily Factor Xa inhibitor anticoagulant in development for the extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The betrixaban poster will include additional data that is not available in the abstract, which is currently available on the ACC website. Betrixaban Abstract Title: Extended Duration Betrixaban Reduces the Risk of Venous Thromboembolism Versus Standard Duration Enoxaparin in the Post Parenteral Period Among Hospitalized Medically Ill Patients
Poster #: 055
Presenting Author: Serge Korjian, M.D., Beth Israel Deaconess Medical Center, Boston 
Session Title: Diabetes and Other Issues in Cardiovascular Prevention 
Presentation Date and Time: Sunday, March 19, 9:45-10:30 a.m. ET
Presentation Location: Poster Hall, Hall C

Presentation Title: Extended Pharmacological Thromboprophylaxis at Hospital Discharge for High Risk Medical Patients
Presenting Author: Alexander (Ander) T. Cohen, MBBS, M.Sc., M.D., FRACP, APEX Co-Principal Investigator and Co-Chairman of the APEX Executive Committee and consultant physician at Guy’s and St Thomas’ NHS Foundation Trust
Session Title: Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention
Session Number: 637
Presentation Date and Time: Friday, March 17, 2:48-3:00 p.m. ET
Presentation Location: Room 209 C AndexXa™ (andexanet alfa) Presentation Title: Managing Life-threatening Bleeding in Patients Taking Non-Vitamin K Oral Anticoagulants: When and How to Use Reversal Agents
Presenting Author: Samuel Goldhaber, M.D., senior physician, Brigham and Women’s Hospital, Boston  
Session Title: Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention
Session Number: 637
Presentation Date and Time: Friday, March 17, 2:24-2:36 p.m. ET
Presentation Location: Room 209 C About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
[email protected]

Media Contact:
Julie Normart
Pure Communications
[email protected]
415.946.1087

Read more...
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:
Cowen and Company’s 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. Eastern Time in Boston.
Oppenheimer’s 27th Annual Healthcare Conference on Wednesday, March 22, 2017, at 1:35 p.m. Eastern Time in New York. Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
[email protected]

Media Contact:
Julie Normart
Pure Communications
[email protected]
415.946.1087

Read more...

Ratios

vs
industry
vs
history
PB Ratio 12.94
PTLA's PB Ratio is ranked lower than
88% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PTLA: 12.94 )
Ranked among companies with meaningful PB Ratio only.
PTLA' s PB Ratio Range Over the Past 10 Years
Min: 3.07  Med: 4.67 Max: 14.64
Current: 12.94
3.07
14.64
PS Ratio 64.24
PTLA's PS Ratio is ranked lower than
80% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. PTLA: 64.24 )
Ranked among companies with meaningful PS Ratio only.
PTLA' s PS Ratio Range Over the Past 10 Years
Min: 5.28  Med: 72.72 Max: 285.93
Current: 64.24
5.28
285.93
EV-to-EBIT -7.70
PTLA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PTLA: -7.70 )
Ranked among companies with meaningful EV-to-EBIT only.
PTLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.2  Med: -7.75 Max: -1.3
Current: -7.7
-13.2
-1.3
EV-to-EBITDA -7.76
PTLA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PTLA: -7.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTLA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.3  Med: -7.85 Max: -1.3
Current: -7.76
-13.3
-1.3
Current Ratio 6.81
PTLA's Current Ratio is ranked higher than
57% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PTLA: 6.81 )
Ranked among companies with meaningful Current Ratio only.
PTLA' s Current Ratio Range Over the Past 10 Years
Min: 5.01  Med: 7.63 Max: 10.67
Current: 6.81
5.01
10.67
Quick Ratio 6.81
PTLA's Quick Ratio is ranked higher than
58% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PTLA: 6.81 )
Ranked among companies with meaningful Quick Ratio only.
PTLA' s Quick Ratio Range Over the Past 10 Years
Min: 5.01  Med: 7.63 Max: 10.67
Current: 6.81
5.01
10.67

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.40
PTLA's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PTLA: -11.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTLA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -201.9  Med: -5.7 Max: 0
Current: -11.4
-201.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.05
PTLA's Price-to-Net-Cash is ranked lower than
73% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. PTLA: 15.05 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PTLA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 6.4 Max: 16.04
Current: 15.05
0
16.04
Price-to-Net-Current-Asset-Value 14.12
PTLA's Price-to-Net-Current-Asset-Value is ranked lower than
75% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PTLA: 14.12 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PTLA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 5.88 Max: 15.05
Current: 14.12
0
15.05
Price-to-Tangible-Book 13.21
PTLA's Price-to-Tangible-Book is ranked lower than
83% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PTLA: 13.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PTLA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 4.76 Max: 14.08
Current: 13.21
3.14
14.08
Price-to-Median-PS-Value 0.88
PTLA's Price-to-Median-PS-Value is ranked higher than
64% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PTLA: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTLA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.91 Max: 3.05
Current: 0.88
0
3.05
Earnings Yield (Greenblatt) % -13.07
PTLA's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PTLA: -13.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTLA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1686.28  Med: 0 Max: 0
Current: -13.07
-1686.28
0

More Statistics

Revenue (TTM) (Mil) $32.37
EPS (TTM) $ -4.35
Beta2.28
Short Percentage of Float11.13%
52-Week Range $15.68 - 42.74
Shares Outstanding (Mil)57.02

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 46 251 476
EPS ($) -5.10 -4.33 -3.22
EPS without NRI ($) -5.10 -4.33 -3.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTLA

Headlines

Articles On GuruFocus.com
Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference May 09 2017 
Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Updat May 08 2017 
Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on May 01 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at AC Mar 07 2017 
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences Mar 01 2017 
Paulson Bets Again On Mallinckrodt Aug 07 2014 

More From Other Websites
ETFs with exposure to Portola Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May... May 22 2017
These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop? May 22 2017
Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at... May 18 2017
Edited Transcript of PTLA earnings conference call or presentation 8-May-17 8:30pm GMT May 13 2017
3 Top Biotech Stocks For May May 11 2017
Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Why Portola Pharmaceuticals Shot 12.8% Higher Today May 09 2017
Portola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : May 9, 2017 May 09 2017
Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference... May 09 2017
Portola Pharmaceuticals posts 1Q loss May 08 2017
Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update May 08 2017
Investor Network: Portola Pharmaceuticals, Inc. to Host Earnings Call May 08 2017
Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on... May 01 2017
Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017 Apr 17 2017
Losing Money on a Stock? Blame Your Brain Apr 10 2017
ETFs with exposure to Portola Pharmaceuticals, Inc. : April 5, 2017 Apr 05 2017
3 Hot Stocks to Buy in April Apr 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)